Ability of two new thiazolidinediones to downregulate proinflammatory cytokines in peripheral blood mononuclear cells from children with asthma

• Published in: Brazilian Journal of Pharmaceutical Sciences Vol. 54; no. 3
• Main Authors: Rêgo, Moacyr Jesus Barreto de Melo, Azoubel-Antunes, Adriana, Bezerra, Mariana Brayner-Cavalcanti Freire, Pereira, Michelly Cristiny, Silva, Juliana Cruz da, Lins, Thiago Ubiratan Lins e, Sarinho, Emanuel Sávio Cavalcanti, Amorim, Cézar Augusto da Cruz, Lima, Maria do Carmo Alves de, Galdino-Pitta, Marina Rocha, Pitta, Ivan da Rocha, Pitta, Maira Galdino da Rocha
• Format: Journal Article
• Language: English; Portuguese
• Published: Sao Paulo Universidade de Sao Paulo Faculdade de Ciencias 01.01.2018; Universidade de São Paulo, Faculdade de Ciências Farmacêuticas; Universidade de São Paulo
• Subjects: Asthma; Cytokines; Ethanol; Expected values; Inflammatory diseases; Laboratories; Ligands; Lymphocytes; NMR; Nuclear magnetic resonance; Pediatrics; PHARMACOLOGY & PHARMACY; Spectrum analysis; Spleen; Th17-related cytokines; Thiazolidinedione derivative; Thiazolidinedione derivative; Asthma; Th17-related cytokines
• ISSN: 2175-9790; 1984-8250; 2175-9790
• DOI: 10.1590/s2175-97902018000300049

Allergic asthma is a chronic, complex inflammatory disease of the airway. Despite extensive studies on the immunomodulation of T helper (Th) cell pathways (i.e., Th1 and Th2) in asthma, little is known about the effects of Th17 pathway modulation, particularly that involving peroxisome proliferator-activated receptors (PPARs). In response, two new thiazolidinedione derivatives-namely, LPSF-GQ-147 and LPSF-CR-35 were synthesized and evaluated for their immunomodulatory effects on Th17-related cytokines, including interferon γ (IFNγ), interleukin IL-6, IL-17, and IL-22 in the peripheral blood mononuclear cells of asthmatic children. Both compounds were nontoxic even at high concentrations (i.e., 100 µM). The LPSF-CR-35 compound significantly reduced the levels of IL-17A (p = .039) and IFNγ (p = .032) at 10 µM. For IL-22 and IL-6, significant reduction occurred at 100 µM (p = .039 and p = .02, respectively). Conversely, LPSF-GQ-147 did not significantly inhibit the production of the tested cytokines, the levels of all of which were more efficiently reduced by LPSF-CR-35 than methylprednisolone, the standard compound. Real-time polymerase chain reaction assay confirmed that LPSF-GQ-147 has significant PPARγ modulatory activity. Such data indicate that both LPSF-CR-35 and LPSF-GQ-147 are promising candidates as drugs for treating inflammation and asthma.